Lexaria Bioscience Corp.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria’s DehydraTECHTM drug delivery platform for enhancing delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19.

Lexaria is an established world-leader in oral delivery of fat-soluble drugs. Lexaria’s patented DehydraTECH technology has already been thoroughly studied and proven to deliver other fat soluble drugs with increases of up to 317% more drug quantified in blood in a human clinical study within the first 30 minutes of dosing as published in a peer-reviewed medical journal.

News Feed